BioVie's announcement regarding a phase 2 trial for its lead therapy helped raise the stock's price.
The company is forging ahead with a phase 3 trial for its lead therapy.
The biotech announced positive news from a pair of phase 2 clinical trials.
The more investors learned about BioVie's latest clinical results, the more they liked.
The clinical-stage biotech released data on its prospective Alzheimer's therapy.
December S&P 500 futures (ESZ22) are trending up +0.08% this morning after three major US benchmark indices finished the regular session sharply lower as market participants fretted that stronger-than-anticipated...
CARSON CITY, Nev., June 23, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative...
CARSON CITY, Nev., March 10, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing innovative drug therapies for the...
RENO, Nev., March 09, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative...
RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug...